- CA$68.96m
- CA$66.97m
- 13
- 24
- 54
- 20
Annual balance sheet for Helix Biopharma, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 4.24 | 3.56 | 3.25 | 0.808 | 1.08 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.18 | 0.353 | 0.279 | 0.062 | 0.054 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.66 | 4.02 | 3.69 | 0.996 | 1.46 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.246 | 0.047 | 0.036 | 0.033 | 0.033 |
| Other Long Term Assets | |||||
| Total Assets | 4.91 | 4.07 | 3.73 | 1.03 | 1.49 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.93 | 3.87 | 3.41 | 1.87 | 1.58 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.51 | 5.46 | 3.41 | 1.87 | 1.58 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.39 | -1.39 | 0.319 | -0.844 | -0.09 |
| Total Liabilities & Shareholders' Equity | 4.91 | 4.07 | 3.73 | 1.03 | 1.49 |
| Total Common Shares Outstanding |